+3,159.9%
CVNA vs GSK
+94.0%
+3,065.9%
-99.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.2% | +0.5% | +1.6% | +1.9% |
| 7D | -1.6% | +1.1% | -2.8% | -2.1% |
| 30D | +24.9% | +6.3% | +18.5% | +21.3% |
| 3M | -1.8% | +1.8% | -3.6% | -3.0% |
| 6M | +3.5% | +1.7% | +1.9% | +1.7% |
| YTD | -14.3% | +6.5% | -20.8% | -18.4% |
| 1Y | +13.6% | +9.5% | +4.1% | +6.4% |
| 3Y | +1,163.4% | +65.3% | +1,098.1% | +749.3% |
| 5Y | +22.9% | +43.7% | -20.8% | -10.0% |
| All | +3,159.9% | +94.0% | +3,065.9% | +1,711.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling